1. Scrip
  2. >>R&D

GSK Halts Enrollment In Maternal RSV Vaccine Trials As Setback Intensifies

 
• By Jessica Merrill

The company has not revealed any details of the potential safety issue that led to the decision.

pregnant woman
GSK's maternal vaccine for RSV faces a setback • Source: Alamy

A setback in the development of GlaxoSmithKline plc's high profile vaccine candidate for respiratory syncytial virus (RSV) has intensified. The company announced on 28 February that rather than just pausing enrollment and vaccination in clinical trials evaluating the vaccine in pregnant women it is halting the trials due to a safety issue that has not been disclosed.

The studies impacted all involve pregnant women, including the Phase III GRACE trial evaluating the safety and efficacy of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.